Is OmniAb (OABI)’s Eli Lilly (LLY) Partnership a Game Changer for OABI?
On August 17, OmniAb, Inc. (NASDAQ:OABI) announced a global collaboration and license agreement with Eli Lilly and Company (NYSE:LLY) to discover and develop novel ion channel therapeutics.





